



維奧醫藥控股有限公司
Vital Pharmaceutical Holdings Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1164)

ANNOUNCEMENT

PRICE SENSITIVE INFORMATION

This announcement is made pursuant to Rule 13.09(1) of the Listing Rules.

Recently, the “Depile Capsules” manufactured by the Group has been informed by the Adverse Drug Reaction Center under the State Food and Drug Administration of the PRC, regarding the report on the case of damage to liver by the “Depile Capsules”. After a systematic analysis undergone in respect to the cases under the report, the relation between the “Depile Capsules” and the case of damage to liver could not be excluded.

The “Depile Capsules” can be used for the treatment of symptoms including hematochezia, the sagging bloat or pain of anus, dry stool or constipation arising from phase I and II of internal hemorrhoids and mixed hemorrhoids.

The manufacture, sales and use of “Depile Capsules” has been suspended at the moment, and the Group has voluntarily recalled the products from the market. Also, the Group has conducted a research on the mechanism of liver damage resulted from the “Depile Capsules” and reassessed the risks and benefits of such drug product.

All “Depile Capsules” have been distributed and sold in the Mainland China only, and are being recalled voluntarily and promptly. As at the date of this announcement, no other products have been recalled other than the “Depile Capsules”.

For the first nine months ended 30 September 2008, the sales of the “Depile Capsules” only accounted for approximately 1.2% of the Group’s turnover, and as at 30 September 2008, the inventories in respect of the “Depile Capsules” were only amounted to approximately HK\$3.4 million. The board of directors of the Group believes that the suspension of the manufacture and sales as well as voluntary recalling of “Depile Capsules” would not result in a material adverse impact on the operations and the financial position of the Group.

The Board wishes to express its deep regrets for the inconvenience caused by the incident as well as to the public.

As at the date of this announcement, the Board comprises six executive directors: Mr. Tao Lung, Mr. Huang Jianming, Mr. Shen Songqing, Mr. Liu James Jin, Mr. Xu Xiaofan and Madam Guo Lin, and three independent non-executive directors: Mr. Lui Tin Nang, Mr. Lee Kwong Yiu and Mr. Chong Cha Hwa.

By Order of the Board
TAO Lung
Chairman

Hong Kong, 12 November 2008